View metadata, citation and similar papers at core.ac.uk
brought to you by CORE
provided by University of Debrecen Electronic Archive

1 **Commercial strain-derived clinical *Saccharomyces cerevisiae* can evolve new phenotypes**
2 **without higher pathogenicity**

3

4 Walter P. Pfliegler[1,2*], Enikő Boros[1], Kitti Pázmándi[3], Ágnes Jakab[1], Imre Zsuga[1], Renátó
5 Kovács[4,5], Edit Urbán[6], Zsuzsa Antunovics[7], Attila Bácsi[3], Matthias Sipiczki[7], László
6 Majoros[4], István Pócsi[1]

7 [1]Department of Biotechnology and Microbiology, University of Debrecen, Debrecen,
8 Hungary;

9 [2]Postdoctoral Fellowship Programme of the Hungarian Academy of Sciences (MTA),
10 Budapest, Hungary;

11 [3]Department of Immunology, University of Debrecen, Debrecen, Hungary;

12 [4]Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary

13 [5]Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary;

14 [6]Institute of Clinical Microbiology, University of Szeged, Szeged, Debrecen;

15 [7]Department of Genetics and Applied Microbiology, University of Debrecen, Debrecen,
16 Hungary

17

18 *Correspondence: Walter P. Pfliegler

19 Dept. of Biotechnology and Microbiology, University of Debrecen, Egyetem tér 1., Debrecen,
20 H4032, Hungary. Tel: +3652512900/62492; Fax: +3652512925; Email:
21 pfliegler.valter@science.unideb.hu

22

23 **Abbreviations: AmB**, amphotericin B; **Flu**, fluconazole; **gDNA**, genomic DNA; **MIC**,
24 minimal inhibitory concentration; **MSB**, menadione sodium bisulfite; **mtDNA**, mitochondrial
25 DNA; **PBMC**, Peripheral blood mononuclear cells; **TNF-α**, Tumor necrosis factor alpha.

26

27 **Keywords:** baking yeast, commensal, microevolution, mycobiom, probiotic

28

29 **Abstract**

30 Scope: *Saccharomyces cerevisiae* is one of the most important microbes in food industry, but
31 there is growing evidence on its potential pathogenicity as well. Its status as a member of
32 human mycobiome is still not fully understood.

33 Methods and results: In this study, we characterise clinical *S. cerevisiae* isolates from
34 Hungarian hospitals along with commercial baking and probiotic strains, and determine their
35 phenotypic parameters, virulence factors, interactions with human macrophages, and
36 pathogenicity. Four of the clinical isolates could be traced back to commercial strains based
37 on genetic fingerprinting. Our observations indicate that the commercial-derived clinical
38 isolates have evolved new phenotypes and show similar, or in two cases, significantly
39 decreased pathogenicity. Furthermore, immunological experiments revealed that the
40 variability in human primary macrophage activation after co-incubation with yeasts is largely
41 donor- and not isolate-dependent.

42 Conclusion: Isolates in this study offer an interesting insight into the potential microevolution
43 of probiotic and food strains in human hosts. These commensal yeasts display various
44 changes in their phenotypes, indicating that the colonization of the host does not necessarily
45 impose a selective pressure towards higher virulence/pathogenicity.

46

47 **1. Introduction**

48 The roles of *Saccharomyces cerevisiae* in producing fermented beverages and in breadbaking
49 have made this yeast one of the most important microbes throughout human history [1, 2]. *S.*
50 *cerevisiae* is a domesticated species with different clades adapted to different fermentation
51 technologies [1, 3]. Its use in various branches of the food industry leads to frequent human
52 exposure to *S. cerevisiae*, and besides probiotics, food-borne yeasts may also have beneficial
53 health effects [4]. The potential of this yeast to colonize the human body has long been
54 suspected, although its status as a transient species [5, 6] or established nature [7, 8] in the
55 human mycobiome is still unclear. *S. cerevisiae* colonization of the gastrointestinal tract may
56 be locally frequent [9].

57 Although *S. cerevisiae* is generally recognized as safe, its colonization of the human body,
58 whether transient or long lasting, may occasionally result in infections (mycoses) [2, 10, 11].
59 Opportunistic *Saccharomyces* infections have become known and reported from patients from
60 a wide range of age groups and underlying diseases [12–16], including systemic mycosis in
61 immunocompromised patients [17]. Multiple methods are in use to characterize the traits of
62 opportunistic pathogenic yeasts, and many of them are referred to as pathogenicity or
63 virulence factors. However, often there is a considerable overlap in clinical and non-clinical
64 strains in virulence traits, as recently reviewed [18]. Besides surveying virulence factors and
65 their correlation with pathogenic potential, understanding the origin of human-related *S.*
66 *cerevisiae* isolates and their relations to the different industrial and natural clades of the
67 species can help us to shed light on how this yeast might evolve commensalism or
68 pathogenicity.

69 Recently, molecular phylogenetic investigations on the global diversity of the species have
70 identified human-adapted *S. cerevisiae* clades that have arisen from multiple opportunistic

71 colonization events [2, 3, 19, 20]. Most of the clinical yeasts were shown to be genetic
72 mosaics, but several isolates were nested in the non-hybrid Wine/European clade of the
73 species [2].

74 Opportunistic pathogenic *S. cerevisiae* isolates derived from baking yeasts have also been
75 identified from patients with or without occupational exposures to baker's yeasts [21–27],
76 although in several cases, the clinical isolates were plausibly commensal [22]. Potential risks
77 of food yeast products were recently reviewed [28].

78 Growing evidence on the pathogenic potential of probiotic-derived *S. cerevisiae* opportunistic
79 pathogens is also available. *S. cerevisiae* probiotics and biotherapeutic agents are marketed as
80 '*S. boulardii*' and advised for patients with dysentery [29]. These strains are asporogenous
81 natural isolates, with moderate [30] or often considerable virulence factors [31, 32].
82 Fungaemia related to a commercial probiotic strain was reported in an intensive care unit and
83 in the case of premature neonates [33, 34]. Consequently, caution was proposed for
84 immunosuppressed patients regarding the use of such probiotics [14, 31]. In the case of
85 immunocompetent hosts, intravenous inoculation with probiotics caused septic shock that was
86 spontaneously cured, indicating that these strains are not highly virulent pathogens [35, 36].

87 Regardless of whether different *Saccharomyces* isolates of the human mycobiome are
88 exogenous opportunists or true commensals in the gut, studying their adaptations related to
89 virulence, possible antimycotic resistance or their interactions with the immune system is
90 important. In our study, we characterized clinical *S. cerevisiae* isolates from Hungary along
91 with dietary and probiotic strains available in the country with genotyping methods and
92 assessed their various phenotypic features and immunostimulatory activity, in order to
93 determine whether the clinical isolates can be traced back to the commercial strains and if so,
94 whether their phenotypes show consistent differences. Using the characterization of

95 commercial strains and four genetically related isolates, we show that these commercial-
96 derived clinical *S. cerevisiae* are apparently subjected to microevolution in the human host.
97
98 **2. Materials and Methods**
99
100 *Strains, isolates and identification.* Isolates were obtained as single-cell colonies from patients
101 in the university clinics in Debrecen and Szeged (Hungary) (isolation data is listed in
102 Supplementary File S1). Strains of baker's, wine and probiotic yeasts were obtained
103 commercially and were given individual identifiers (Supplementary File S1).

104 *Genetic characterization.* Interdelta fingerprinting [37] was used for strain typing and applied
105 to establish genetic relatedness of strains and isolates. The strain-isolate pairs with identical or
106 near identical patterns were considered having a very recent common (commercial) ancestor.
107 These yeasts were further subjected to karyotyping, RAPD-PCR, microsatellite PCR, and
108 mitochondrial DNA-RFLP to confirm their genetic similarity and close relatedness. Methods
109 for typing are listed in Supplementary File S1.

110 *Phenotypic characterization.* The sporulation capability, colony morphology, pseudohyphal
111 and invasive growth, susceptibility to antifungal and oxidative stress generating agents,
112 growth under osmotic, chemical and high temperature stress conditions, extracellular
113 hydrolytic enzyme production, and hemolytic activity were assessed for all yeast isolates and
114 strains to provide a broad overview of their phenotypic characteristics, with methods
115 described in Supplementary File S1 in detail.

116 *Damage assay* was conducted using a Cytotoxicity Detection Kit - LDH (Hoffmann-La
117 Roche, Basel, Switzerland) with Caco-2 cell monolayer in 96-well plates following the
118 manufacturer's protocol as described in Supplementary File S1.

119 *Insect pathogenicity model.* The *Galleria mellonella* larva pathogenicity model [38] was used
120 to assess the pathogenicity of the strains and isolates *in vivo*. This model enables the rapid
121 assessment of the pathogenicity of opportunistic fungi (e.g. *Candida* spp) on a large number
122 of infected hosts and is comparable to murine models [39]. Details of the experiments are
123 listed in Supplementary File S1.

124 *Immunological experiments.* Phagocytosis assay using flow cytometry and phenotypic and
125 functional analysis of yeast-exposed human primary macrophages differentiated from four
126 healthy donors' PBMCs were used to assess immune activation by the individual strains and
127 isolates. Experimental procedures and PBMC isolation and macrophage differentiation are
128 described in Supplementary File S1.

129 *Statistics.* Measurements carried out in triplicates (hemolysis, extracellular enzyme activity,
130 damage and phagocytosis assays) and quadruplicates (macrophage phenotype) allowed
131 statistical comparisons among different yeast strains and isolates, as described in
132 Supplementary File S1.

133

134 **3. Results**

135

136 *Fingerprinting and relations among the strains and isolates*

137 For strain typing, the resolution of interdelta fingerprinting and microsatellite typing for two
138 loci were compared. All three combinations of interdelta PCR resulted in distinct fingerprints
139 for all commercial yeasts, while both microsatellite analyses were unable to distinguish
140 between two of the baking strains (BY2 and BY3) (Supplementary File S2). We thus relied
141 primarily on interdelta fingerprinting to assess the genetic relatedness among the commercial
142 strains and the clinical isolates, similarly to previous works [26-27]. The strains and isolates
143 with identical or highly similar fingerprinting patterns (Figure 1 a-c) were further
144 characterized by microsatellite typing, RAPD-PCR, mtDNA-RFLP, and karyotyping (Figure
145 1 d-h).

146 The combined use of three primer combinations for interdelta-PCR resulted in a dendrogram
147 that showed the following clusterings of commercial and clinical yeasts: the isolate Sz1 (from
148 cervix) with the baking strain BY1; the isolates Sz7 and Sz9 (from stomach and throat,
149 respectively) with BY2; and isolate DE27020 (from bronchus) with PY1 (Supplementary File
150 S1-2). Pattern identity (isolates Sz7, Sz9, DE27020) or high similarity (isolates Sz1) between
151 commercial strains and certain clinical isolates strongly implies common ancestry, meaning
152 that these clinical isolates are derived from commercial yeasts and share very recent common
153 ancestors with the given batches of commercial yeasts analyzed in this study. The common
154 ancestors of the commercial-clinical counterparts are plausibly batches of the same
155 commercial yeasts manufactured earlier (especially in the case of yeasts with pattern identity),
156 or closely related yeasts commercialized under different trade marks. Furthermore, the
157 isolates Sz8 and DE27290 were also found to group together with baking strains BY1, BY2
158 and BY3 (Supplementary File S2), implying some level of genetic relatedness.

159 Microsatellite, mtDNA-RFLP and RAPD-PCR band patterns were identical in the case of all
160 commercial-clinical counterparts identified by interdelta analysis. However, mtDNA-RFLP
161 patterns were also indistinguishable between BY1 and BY2. Microsatellite analysis identified

162 tri- and tetraallelic strains and isolates (Supplementary File S2), suggesting poly- or
163 aneuploidy. Karyotyping produced distinct chromosomal band patterns for the two baking and
164 the probiotic yeast (Figure 1). All baking yeasts and their clinical counterparts possessed
165 supernumerary bands in the region of small chromosomes (chromosomes I, VI and III): two
166 extra bands in the case of BY1 and one in Sz1, and two bands in the case of BY2 and its
167 counterparts (identical among these yeasts) (Supplementary File S2). Chromosome II showed
168 size polymorphism when BY1 and Sz1 were compared. An additional supernumerary band
169 was observed for BY2 and its counterparts between chromosomes V and XI (Supplementary
170 File S2). Thus, BY2 and its counterparts Sz7 and Sz9, and PY1 and its counterpart DE27020
171 showed identical karypotypes, whereas BY1 and Sz1 showed occasional polymorphism in
172 chromosome sizes.

173

174 *Characteristics of clinical isolates related to baking yeast strains.*

175 Data on phenotypic features and virulence factors enabled us to compare clinical isolates and
176 their commercial counterparts (the clinical isolates and the commercial strains that showed the
177 highest genetic similarity, in some cases identity, with these, viz. PY1 and DE27020; BY1
178 and Sz1; BY2 and Sz7, Sz9). Table 1 highlights the phenotypic differences between these
179 strain/isolate pairs.

180 The isolate Sz1, as compared to the baking yeast BY1 (Table 1), showed decreased
181 sporulation rate (40% *vs.* 90%). The pseudohyphae of Sz1 were short, while BY1 possessed
182 long chain-like pseudohyphae. Sz1 showed reduced growth at 39°C compared to the baker's
183 strain (Supplementary File S3). Tolerance of sulfite and pH8 stress was higher in Sz1.
184 Phospholipase activity was not significantly different at 30°C, but at 37°C the baker's strain
185 showed a significantly higher activity ($p<0.01$). Higher protease activity ($p<0.05$) and β

186 hemolytic activity ($p<0.01$) were found in the clinical isolate. Pathogenicity in the insect
187 model, as well as macrophage phenotypes and phagocytosis after exposure to BY1 and Sz1
188 were highly similar (Table 1, Supplementary Files S3-S5).

189 Differences among the clinical isolates Sz7 and Sz9 and the baking strain BY2 included
190 colony morphology, sporulation ability, cell size, invasive growth into the agar medium, and
191 tolerance of high temperature (Table 1, Supplementary File S3). Tolerance of sulfite and NaCl
192 stress was elevated in the case of both clinical isolates. Copper stress tolerance was decreased
193 in Sz9. Both clinical isolates were unable to grow at pH 8, while BY2 displayed weak growth
194 (Supplementary File S3). Phosholipase activity of the baker's strain at 37°C was significantly
195 higher than that of Sz7 ($p<0.05$). At 30°C, BY2 did not display lipolytic activity, while both
196 clinical isolates were lipolytic. Proteolytic activity of Sz9 was significantly elevated ($p<0.05$).
197 The α-hemolytic activity was elevated in the case of Sz9 and lower in the case of Sz7 after 1 d
198 ($p<0.05$), and elevated in the case of Sz7 after 2 d ($p<0.05$). β-hemolytic activity was
199 significantly higher in the case of Sz7 ($p<0.01$) and Sz9 ($p<0.001$) (Table 1). Pathogenicity in
200 the *Galleria* larvae showed remarkable differences between these yeasts. The strain BY2
201 killed 30 % of the inoculated larvae and the survival rates of Sz7 and Sz9 were significantly
202 higher: Sz7 killed only 5 % of the larvae ($p<0.05$) and all larvae inoculated with Sz9 survived
203 ($p<0.01$) (Supplementary File S5). Significant differences were not found in the case of
204 macrophage phenotypes and phagocytosis after exposure to BY2 and the two isolates
205 (Supplementary Files S3-4).

206

207 *Characteristics of the clinical isolate related to the probiotic yeast.*

208 The isolate DE27020 showed minor differences in phenotypes when compared to the
209 probiotic strain PY1 (Table 1). At 39°C, DE27020 showed stronger growth than PY1

210 (Supplementary File S3). Lack of sporulation, colony and pseudohyphal morphology, and cell
211 size were remarkably similar (Supplementary File S3). The clinical isolate's tolerance to
212 sulfite and lithium stress was elevated compared to PY1, while other tested stress factors did
213 not show such differences. Extracellular hydrolase production was highly similar for both
214 yeasts. Damage assay conducted on Caco-2 epithelial cells revealed an elevated cell damage
215 ($p<0.01$) in the monolayer when exposed to DE27020. However, both yeasts caused relatively
216 low cell death when compared to the high control (Table 1, Supplementary File S3).
217 Pathogenicity in the larva model was similarly very low in the case of both yeasts
218 (Supplementary File S5). No significant difference was found when the extent of
219 phagocytosis or macrophage phenotypes were compared (Table 1, Supplementary Files S3-4).

220

221 **4. Discussion**

222

223 To determine if any of the clinical isolates can be traced back to commercial *S. cerevisiae*
224 strains used in the food industry, we applied interdelta genotyping. This method has been
225 applied to identify commercial derived clinical isolates before [26-27] and our results showed
226 that it has a better resolution as microsatellite typing, mtDNA-RFLP or RAPD also applied in
227 this study. We identified three clinical isolates as baker's yeast- and one as probiotic-derived,
228 and the similarity between the genotyping profiles enabled us to propose very recent common
229 ancestry for these clinical yeasts and three of the commercial yeast strain batches used in this
230 study (common ancestors are plausably batches of the same commercial yeasts manufactured
231 earlier, especially in the case of identical genotyping markers, or genetically highly similar
232 commercial yeasts). This genetic relationship among certain isolates and baker's or probiotic
233 strains was further backed by identical microsatellite alleles, identical RAPD-patterns,

234 identical mtDNA-RFLP profiles and identical or highly similar karyotypes. The presence of
235 two to four microsatellite alleles, occasional changes in interdelta fingerprints, and the small
236 variations in karyotypes in the case of the baker's yeast BY1 and its clinical counterpart Sz1
237 suggests that these yeasts possess an polyploid/aneuploid genome that is more prone to
238 changes than that of the PY1 probiotic yeast's and its clinical counterpart's genome. This
239 observation of occasional variability that is well known among yeasts subjected to
240 microevolution in different environments [40,41 and references therein] is also in
241 concordance with the fact that the baker's yeasts and their counterparts are capable of
242 sporulation, while PY1 and DE27020 are asporogenous. Additionally, some closely related
243 clinical isolates of undetermined affilities (*viz.* Sz2, Sz3, Sz4 and Sz5) also showed no
244 sporulation (or <1 % sporulation) and these isolates also displayed some differences in
245 phenotypes but had identical interdelta profiles (Supplementary File S2-5).

246 Each of the commercial-derived clinical isolates in this study were sampled from different
247 patients, from anatomical parts such as cervix, stomach, throat, and bronchus, on different
248 dates and thus represent individual colonization events. None of the patients were diagnosed
249 with *S. cerevisiae* fungaemia, thus their isolates may have been either (i) pathogens not
250 causing fungaemia at the time of sampling; (ii) non-pathogenic yeasts with commensal
251 adaptations; or (iii) recently ingested commercial strains transiently associated with the
252 patients. The latter scenario is unlikely as all isolates displayed various phenotypes and often
253 some level of genetic variability when compared to the genetically most similar commercial
254 yeasts, thus these isolates have apparently already been subjected to microevolution after the
255 colonization of the hosts. Additionally, the *Galleria* pathogenicity model did not indicate high
256 pathogenicity for the isolates, thus the most likely scenario is a commensal lifestyle.

257 Phenotypic characterization not only revealed differences between the commercial strains and
258 their clinical counterparts but also among the clinical isolates, including differences between

259 Sz7 and Sz9, two isolates genetically indistinguishable from BY2 (Table 1). Elevated or
260 impaired growth at higher temperatures, a possible virulence factor of the species [42,43] and
261 other opportunistic fungi as well, was both found in the case of the isolates, without changed
262 invasive growth. Similarly to clinical isolates tested previously [43], none of the yeasts in this
263 study were able to grow at 42°C. As noted before [18], growth and phenotype at temperatures
264 higher than 37°C may be important, but not crucial in virulence. Sulfite tolerance,
265 interestingly, was uniformly elevated in the clinical isolates. Only one isolate displayed
266 changes in lithium and and one in copper tolerance. It is unclear how these traits are related to
267 pathogenicity but higher lithium and copper tolerance have been found among pathogenic
268 yeasts [44, 45]. Susceptibility testing to antimycotics or MSB showed only minor differences
269 among the strains and their clinical counterparts.

270 Differences in the production of extracellular hydrolytic enzymes were commonly observed:
271 isolates either showed reduced or unaltered phospolipase activities and elevated or unaltered
272 protease activities at the host's physiological temperature. Hemolytic activity was more
273 pronounced in the case of all baker's yeast derived isolates (Table 1). Damage assay with
274 Caco-2 epithelial cells revealed significant differences only in one strain–isolate pair (PY1
275 and DE27020).

276 Pathogenicity of the yeasts in this study was assessed using the *Galleria* larva model, which is
277 capable of providing generalized information on the pathogenicity of a wide range of
278 microorganisms [39, 46]. In our study, only few yeasts were able to significantly decrease
279 larval survival (Supplementary File S5). PY1 and DE27020, BY1 and Sz1 had no significant
280 effect on the larvae's survival. Significant pathogenicity was found in the case of the baker's
281 strain BY2, while it's clinical counterparts were non-pathogenic (isolates Sz7 and Sz9).

282 Phagocytosis experiments and characterization of the macrophage activation were carried out
283 using primary macrophages from three and four (respectively) different healthy donors.
284 Macrophages are known for their phagocytic activity and antigene presentation in peripheral
285 tissues, and understanding how they form the first line of defence during yeast infections is
286 crucial [47, 48]. Our experimental design allowed us to evaluate if the macrophage responses
287 to yeasts are mostly dependent on the individual strain/isolate or the individual donor. The
288 latter scenario is backed by our data, as high variances between individual donors were found
289 (Supplementary Files S3-4). The macrophages of four different donors not only showed
290 remarkable differences in their activation and phenotypes after co-incubation with a given
291 yeast, but many yeasts induced relatively weak activation in the case of some donors while
292 inducing very high relative activation in others. This variability was marked for most of the
293 tested macrophage features when all 19 yeasts were compared (Supplementary File S4).
294 These donor-dependent differences (that apparently mask strain and even strain-group level
295 differences in macrophage activation) have previously not been uncovered, as experiments are
296 usually conducted using one donor – one yeast strain setups [49, 50]. As proinflammatory
297 processes have been associated with increased virulence of the species [46], donor dependent
298 differences in phagocyte activation may be important in future studies on virulent and
299 avirulent *S. cerevisiae*.

300 Relatively rapid microevolutionary changes that influence the biology of opportunistic fungi
301 have been found previously [51] in the case of other species. To the best of our knowledge,
302 our results are the first to imply that commercial-derived *S. cerevisiae* baker's yeasts may
303 evolve under an apparently commensal lifestyle with altered phenotypes but without elevated
304 pathogenicity (often clearly decreased pathogenicity). As humans may come into contact with
305 industrial strains of fungi on a daily basis, assessing the phenotypes, epidemiology and the
306 potential evolution towards a pathogenic or commensal lifestyle of these fungi is relevant

307 from the aspects of clinical as well as evolutionary microbiology. Yeasts are often
308 excreted/cleared from the human body but their fate is apparently more complex [36, 52, 53].
309 Yeasts may also become commensal or opportunistic. These possibilities are summarized in
310 Figure 2. The phenotypic features including virulence factors observed in the cases of the
311 commercial-derived isolates in this study might represent responses to adaptive pressures
312 inside the human host (*e.g.* changed stress tolerance) or, on the contrary, a relaxed selection
313 compared to the circumstances under industrial strain selection (*e.g.* decreased phospholipase
314 activity).

315 Yeasts, especially *S. cerevisiae* are species of clinical interest and simultaneously model
316 organisms in this field. Here, we have found indication that commercial food strains of the
317 species are capable of persisting as commensals in different niches of the human body for
318 periods long enough to allow microevolutionary changes, resulting in isolates possessing
319 genetic markers identical to, or very similar to commercial strains, but having distinct
320 phenotypes. The diverse phenotypes of commercial-derived isolates suggest no selective
321 pressure towards higher virulence and pathogenicity during this process. Further studies
322 involving phenotypic analysis and genomics of different *Saccharomyces* strains and isolates
323 may provide an unprecedented insight into how our most widely used domesticated microbe
324 evolves in human hosts and help us to better understand its pathogenic potential.

325

326 **Author contributions**

327 W.P.P. and I.P. designed project and experiments. E.U., R.K. & L.M. collected and identified
328 isolates, and collected patient data. W.P.P., E.B., Á.J. & I.Zs conducted phenotypic
329 experiments. K.P., A.B., W.P.P. & E.B. conducted immunological experiments. W.P.P., E.B.,

330 Z.A., & M.S. conducted and evaluated genetic experiments. W.P.P., I.Zs. & E.B. compiled
331 literature data. W.P.P., E.B. & I.P. wrote the article.

332

333 **Acknowledgments**

334 W.P.P. acknowledges the support of the Postdoctoral Fellowship Programme of the
335 Hungarian Academy of Sciences (MTA). We are grateful to Eszter Róka (Dept. of
336 Pharmaceutical Technology, UD) & Zoltán Mészár (Dept. of Anatomy, Histology and
337 Embryology, UD). We thank the staff and MSc students of the Dept. of Biotechnology and
338 Microbiology, Dept. of Genetics and Applied Microbiology, and that of the Dept. of
339 Immunology for support. We are grateful for two anonymous reviewers for valuable
340 comments and additions to this work.

341

342 **Conflict of Interest**

343 The authors declare no conflict of interest.

344

345 **5. References**

346 [1] Legras, J.-L., Merdinoglu, D., Cornuet, J.-M., Karst, F., Bread, beer and wine:
347 *Saccharomyces cerevisiae* diversity reflects human history. *Mol. Ecol.* 2007, *16*, 2091–
348 102.
349 [2] Strope, P.K., Skelly, D.A., Kozmin, S.G., Mahadevan, G., et al., The 100-genomes
350 strains, an *S. cerevisiae* resource that illuminates its natural phenotypic and genotypic
351 variation and emergence as an opportunistic pathogen. *Genome Res.* 2015, *125*, 762–
352 774.
353 [3] Gallone, B., Steensels, J., Baele, G., Maere, S., et al., Domestication and divergence of
354 *Saccharomyces cerevisiae* beer yeasts. *Cell* 2016, *166*, 1397–1410.e16.
355 [4] Moslehi-Jenabian, S., Pedersen, L.L., Jespersen, L., Beneficial effects of probiotic and
356 food borne yeasts on human health. *Nutrients* 2010, *2*, 449–73.
357 [5] Huffnagle, G.B., Noverr, M.C., The emerging world of the fungal microbiome. *Trends*

358 *Microbiol.* 2013, *21*, 334–341.
359 [6] Hallen-Adams, H.E., Suhr, M.J., Fungi in the healthy human gastrointestinal tract.
360 *Virulence* 2016, 1–7.
361 [7] Rizzetto, L., De Filippo, C., Cavalieri, D., Richness and diversity of mammalian fungal
362 communities shape innate and adaptive immunity in health and disease. *Eur. J.*
363 *Immunol.* 2014, *44*, 3166–3181.
364 [8] Scanlan, P.D., Marchesi, J.R., Micro-eukaryotic diversity of the human distal gut
365 microbiota: qualitative assessment using culture-dependent and -independent analysis
366 of faeces. *ISME J.* 2008, *2*, 1183–1193.
367 [9] Angebault, C., Djossou, F., Abélanet, S., Permal, E., et al., *Candida albicans* is not
368 always the preferential yeast colonizing humans: A study in Wayampi amerindians. *J.*
369 *Infect. Dis.* 2013, *208*, 1705–1716.
370 [10] Goldstein, A.L., McCusker, J.H., Development of *Saccharomyces cerevisiae* as a
371 model pathogen: A system for the genetic identification of gene products required for
372 survival in the mammalian host environment. *Genetics* 2001, *159*, 499–513.
373 [11] Muller, L.A.H., Lucas, J.E., Georgianna, D.R., McCusker, J.H., Genome-wide
374 association analysis of clinical vs. nonclinical origin provides insights into
375 *Saccharomyces cerevisiae* pathogenesis. *Mol. Ecol.* 2011, *20*, 4085–97.
376 [12] Enache-Angoulvant, A., Hennequin, C., Invasive *Saccharomyces* Infection: A
377 Comprehensive Review. *Clin. Infect. Dis.* 2005, *41*, 1559–1568.
378 [13] Murphy, A., Kavanagh, K., Emergence of *Saccharomyces cerevisiae* as a human
379 pathogen. *Enzyme Microb. Technol.* 1999, *25*, 551–557.
380 [14] Chioukh, F.Z., Ben Hmida, H., Ben Ameur, K., Toumi, A., et al., Septicémie à
381 *Saccharomyces cerevisiae* chez un prématuré traité par Ultra-Levure®. *Med. Mal.*
382 *Infect.* 2013, *43*, 359–360.
383 [15] Hamoud, S., Keidar, Z., Hayek, T., Recurrent *Saccharomyces cerevisiae* fungemia in
384 an otherwise healthy patient. *Isr. Med. Assoc. J.* 2011, *13*, 575–576.
385 [16] Jensen, D.P., Smith, D.L., Fever of unknown origin secondary to brewer's yeast
386 ingestion. *Arch. Intern. Med.* 1976, *136*, 332–3.
387 [17] Chitasombat, M.N., Kofteridis, D.P., Jiang, Y., Tarrand, J., et al., Rare opportunistic
388 (non-*Candida*, non-*Cryptococcus*) yeast bloodstream infections in patients with cancer.
389 *J. Infect.* 2012, *64*, 68–75.
390 [18] Anoop, V., Rotaru, S., Shwed, P.S., Tayabali, F.S. et al., Review of current methods
391 for characterizing virulence and pathogenicity potential of industrial *Saccharomyces*
392 *cerevisiae* strains towards humans. *FEMS Yeast Res.* 2015, 15, pii: fov057.
393 [19] Zhu, Y.O., Sherlock. G., Petrov, D.A., Whole genome analysis of 132 clinical
394 *Saccharomyces cerevisiae* strains reveals extensive ploidy variation. *G3 (Bethesda)*
395 2016, 6: 2421–2434.
396 [20] Liti, G., Carter, D.M., Moses, A.M., Warringer, J., et al., Population genomics of
397 domestic and wild yeasts. *Nature* 2009, *458*, 337–41.
398 [21] Hennequin, C., Thierry, A., Richard, G.F., Lecointre, G., et al., Microsatellite typing as
399 a new tool for identification of *Saccharomyces cerevisiae* strains. *J. Clin. Microbiol.*
400 2001, *39*, 551–559.
401 [22] Clemons, K. V, Salonen, J.H., Issakainen, J., Nikoskelainen, J., et al., Molecular
402 epidemiology of *Saccharomyces cerevisiae* in an immunocompromised host unit.
403 *Diagn. Microbiol. Infect. Dis.* 2010, *68*, 220–227.
404 [23] Choi, G., Meijer, S.L., Hazenberg, M.D., Disseminated bread yeast fungaemia in a
405 baker's wife with acute myeloid leukaemia. *Br. J. Haematol.* 2012, *158*, 298–298.
406 [24] Seng, P., Cerlier, A., Cassagne, C., Coulange, M., et al., *Saccharomyces cerevisiae*
407 osteomyelitis in an immunocompetent baker. *IDCases* 2016, *5*, 1–3.

408 [25] Nyirjesy, P., Vazquez, J.A., Ufberg, D.D., Sobel, J.D., et al., *Saccharomyces cerevisiae*
409 vaginitis: Transmission from yeast used in baking. *Obstet. Gynecol.* 1995, *86*, 326–
410 329.
411 [26] de Llanos, R., Querol, A., Planes, A.M., Fernández-Espinar, M.T., Molecular
412 characterization of clinical *Saccharomyces cerevisiae* isolates and their association
413 with non-clinical strains. *Syst. Appl. Microbiol.* 2004, *27*, 427–35.
414 [27] de Llanos, R., Querol, A., Pemán, J., Gobernado, M., et al., Food and probiotic strains
415 from the *Saccharomyces cerevisiae* species as a possible origin of human systemic
416 infections. *Int. J. Food Microbiol.* 2006, *110*, 286–90.
417 [28] Pérez-Torrado, R., Querol, A., Opportunistic strains of *Saccharomyces cerevisiae*: A
418 potential risk sold in food products. *Front. Microbiol.* 2015, *6*, 1522.
419 [29] Stier, H., Bischoff, S.C., Influence of *Saccharomyces boulardii* CNCM I-745 on the
420 gut-associated immune system. *Clin. Exp. Gastroenterol.* 2016, *9*, 269–279.
421 [30] McCullough, M.J., Clemons, K. V, Mccusker, J.H., Stevens, D.A., Species
422 identification and virulence attributes of *Saccharomyces boulardii* (nom. inval.). *J.*
423 *Clin. Microbiol.* 1998, *36*, 2613–2617.
424 [31] Llopis, S., Hernández-Haro, C., Monteoliva, L., Querol, A., et al., Pathogenic potential
425 of *Saccharomyces* strains isolated from dietary supplements. *PLoS One* 2014, *9*,
426 e98094.
427 [32] de Llanos, R., Llopis, S., Molero, G., Querol, A., et al., In vivo virulence of
428 commercial *Saccharomyces cerevisiae* strains with pathogenicity-associated
429 phenotypical traits. *Int. J. Food Microbiol.* 2011, *144*, 393–399.
430 [33] Cassone, M., Serra, P., Mondello, F., Girolamo, A., et al., Outbreak of *Saccharomyces*
431 *cerevisiae* subtype *boulardii* fungemia in patients neighboring those treated with a
432 probiotic preparation of the organism. *J. Clin. Microbiol.* 2003, *41*, 5340–5343.
433 [34] Muñoz, P., Bouza, E., Cuenca-Estrella, M., Marı, J., et al., *Saccharomyces cerevisiae*
434 fungemia: An emerging infectious disease. *Clin. Infect. Dis.* 2005, *40*, 1625–1634.
435 [35] Cohen, L., Ranque, S., Raoult, D., *Saccharomyces cerevisiae boulardii* transient
436 fungemia after intravenous self-inoculation. *Med. Mycol. Case Rep.* 2013, *2*, 63–64.
437 [36] Fung, K.S., Scheel, O., Lyon, D.J., Cheng, A.F., et al., Self-inflicted bacteraemia and
438 fungaemia in Vietnamese migrants. *Scand. J. Infect. Dis.* 1996, *28*, 83–5.
439 [37] Pfliegler, W.P., Sipiczki, M., Does fingerprinting truly represent the diversity of wine
440 yeasts? A case study with interdelta genotyping of *S. cerevisiae* strains. *Lett. Appl.*
441 *Microbiol.* 2016, *63*, 406–411.[38] Cotter, G., Doyle, S., Kavanagh, K.,
442 Development of an insect model for the in vivo pathogenicity testing of yeasts. *FEMS*
443 *Immunol. Med. Microbiol.* 2000, *27*, 163–169.
444 [39] Junqueira, J.C., *Galleria mellonella* as a model host for human pathogens: recent
445 studies and new perspectives. *Virulence* 2012, *3*, 474–6.
446 [40] Sipiczki, M., Diversity, variability and fast adaptive evolution of the wine yeast
447 *Saccharomyces cerevisiae* genome—a review. Ann. Microbiol. 2011. *61*, 85–93.
448 [41] Lopandic, K., Pfliegler, W.P., Tiefenbrunner, W., Gangl, H., Sipiczki, M., Sterflinger
449 K, Genotypic and phenotypic evolution of yeast interspecies hybrids during high-sugar
450 fermentation. *Appl. Microbiol. Biotechnol.* 2016, *100*, 6331–43.
451 [42] McCusker, J.H., Clemons, K.V., Stevens, D.A., Davis, R.W., *Saccharomyces*
452 *cerevisiae* virulence phenotype as determined with CD-1 mice is associated with the
453 ability to grow at 42 degrees C and form pseudohyphae. *Infect. Immun.* 1994, 62,
454 5447–5455.
455 [43] Klingberg, T.D., Lesnik, U., Arneborg., N., Raspor, P. et al., Comparison of
456 *Saccharomyces cerevisiae* strains of clinical and nonclinical origin by molecular typing
457 and determination of putative virulence traits. *FEMS Yeast Res.* 2008, 8, 631–640.

458 [44] Strope, P.K., Skelly, D.A., Kozmin, S.G., Mahadevan, G., et al., The 100-genomes
459 strains, an *S. cerevisiae* resource that illuminates its natural phenotypic and genotypic
460 variation and emergence as an opportunistic pathogen. *Genome Res.* 2015, *25*, 762–
461 774.
462 [45] Ding, C., Festa, R.A., Chen, Y.L., Espart, A., et al., *Cryptococcus neoformans* copper
463 detoxification machinery is critical for fungal virulence. *Cell Host Microbe* 2013, *13*,
464 265–276.
465 [46] Ramarao, N., Nielsen-Leroux, C., Lereclus, D., The insect *Galleria mellonella* as a
466 powerful infection model to investigate bacterial pathogenesis. *J. Vis. Exp.* 2012,
467 e4392.
468 [47] Wheeler, R.T., Kupiec, M., Magnelli, P., Abeijon, C., Fink, G.R. A *Saccharomyces*
469 *cerevisiae* mutant with increased virulence. *Proc. Natl. Acad. Sci. USA* 2003, 100,
470 2766–2770.
471 [48] Seider, K., Heyken, A., Luttich, A., Miramon, P., et al., Interaction of pathogenic
472 yeasts with phagocytes: survival, persistence and escape. *Curr. Opin. Microbiol.* 2010,
473 13: 392–400.
474 [49] Smith, I.M., Christensen, J.E., Arneborg, N., Jespersen, L., Yeast modulation of human
475 dendritic cell cytokine secretion: An in vitro study. *PLoS One* 2014, *9*, 12–14.
476 [50] Yáñez, A., Murciano, C., Llopis, S., Fernández-espinar, T., et al., In Vivo and In Vitro
477 Studies on Virulence and Host Responses to *Saccharomyces cerevisiae* Clinical and
478 Non-Clinical Isolates. *Open Mycol. J.* 2009, *3*, 37–47.
479 [51] Magditch, D.A., Liu, T.B., Xue, C., Idnurm, A., DNA Mutations Mediate
480 Microevolution between Host-Adapted Forms of the Pathogenic Fungus *Cryptococcus*
481 *neoformans*. *PLoS Pathog.* 2012, *8*, e1002936.
482 [52] Moré, M.I., Swidsinski, A., *Saccharomyces boulardii* CNCM i-745 supports
483 regeneration of the intestinal microbiota after diarrheic dysbiosis – a review. *Clin. Exp.*
484 *Gastroenterol.* 2015, *8*, 237–255.
485 [53] Cohen, L., Ranque, S., Raoult, D., *Saccharomyces cerevisiae boulardii* transient
486 fungemia after intravenous self-inoculation. *Med. Mycol. Case Rep.* 2013, *2*, 63–64.

Figure 1.

Comparison of commercial yeasts' and their clinical counterparts' genotyping profiles. a: interdelta fingerprinting with primers delta1-2. b: interdelta fingerprinting with primers delta12-2. c: interdelta fingerprinting with primers delta12-21. d: RAPD pattern with primer 24. e: microsatellite typing for locus YPL009c. f: microsatellite typing for locus YOR267c. g: mtDNA-RFLP with enzyme RsaI. h: electrophoretic karyotype. Lane 1: BY1. Lane 2: Sz1. Lane 3: BY2. Lane 4: Sz7. Lane 5: Sz9. Lane 6: PY1. Lane 7: DE27020.

Figure 2.

Possible outcomes of the intake of *S. cerevisiae* probiotic and baker's strains: clearence, commensal, or pathogenic persistence with studies describing these highlighted. Question mark represents inconclusive records (*e.g.* the pathogenicity of isolates was not estimated).

Table 1.

Phenotypic differences in commercial–clinical yeast pairs. Each clinical isolate is compared to the commercial counterpart. Significant changes in the obtained continuous values, >twofold differences in MIC values, and differences in stress tolerance, pseudohyphal type, etc. are indicated.

Supplementary File S1.

Supplementary File 1: Supplementary materials and methods.

509 Supplementary File S2.

510 Supplemtary File S2. Comparison of commercial strains using interdelta and microsatellite
511 typing; interdelta genotyping and dendrogram of the strains and isolates; chromosomal band
512 patterns and chromosome polymorphisms of the strains and their clinical counterparts.

513

514 Supplementary File S3.

515 Supplementary file 3. Phenotypic features and macrophage interactions of the commercial
516 strains and clinical isolates (measurements).

517

518 Supplementary File S4.

519 Macrophage activation and extent of phagocytosis of the commercial strains and clinical
520 isolates. Donor-dependent differences are visualized as web graphs of obtained fold-change
521 values. Phagocytosis visualized with confocal laser scanning microscopy is presented for the
522 strain PY1.

523

524 Supplementary File S5.

525 Survival data and statistics of larvae inoculated with different commercial yeast strains and
526 clinical isolates.